A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population

Trial Profile

A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2014

At a glance

  • Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary) ; Anthrax vaccine
  • Indications Anthrax
  • Focus Adverse reactions
  • Sponsors PharmAthene
  • Most Recent Events

    • 14 Sep 2008 Actual end date has been changed from Jan 2007 to Feb 2007 as reported by ClinicalTrials.gov.
    • 14 Sep 2008 PharmAthene reported as trial sponsor and affliate by ClinicalTrials.gov.
    • 14 Sep 2008 Primary endpoint identified as safety as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top